Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.43 |
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | GSK3B | P49841 | 4/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6894198 | 0.89 | MAOB (0.43) | KDM4EMAPTALDH1A1NPC1RAB9A | |
| SCHEMBL6889233 | 0.85 | KDM4E (0.44) | KDM4EMAPTALDH1A1NPC1RAB9A | |
| SCHEMBL31404504 | 0.83 | CDK2 (0.49) | GSK3BCDK2 | |
| SCHEMBL6889262 | 0.81 | CDK2 (0.56) | GSK3BCDK2 | |
| SCHEMBL1918027 | 0.80 | GSK3B (0.66) | GSK3BCDK2 | |
| SCHEMBL23508047 | 0.79 | GSK3B (0.43) | GSK3BCDK2 | |
| SCHEMBL6895325 | 0.77 | SRC (0.47) | KDM4EALDH1A1KMT2AGSK3BCYP1A2 | |
| SCHEMBL23497833 | 0.77 | PDE10A (0.44) | GSK3BCDK2IGF1R | |
| SCHEMBL23497457 | 0.77 | PKM (0.43) | KDM4EMAPTALDH1A1NPC1RAB9A | |
| SCHEMBL6889153 | 0.76 | SRC (0.49) | KDM4EMAPTALDH1A1GSK3BCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040048849-A1 | Cyclin-dependent kinase (cdk) and glycolene synthase kinase-3 (gsk-3) inhibitors | IPSEN PHARMA S.A.S. (FR) | 2004-03-11 | — | — | US | claimed |
| EP-1345941-A1 | CYCLIN-DEPENDENT KINASE (CDK) AND GLYCOLENE SYNTHASE KINASE-3 (GSK-3) INHIBITORS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2003-09-24 | — | — | EP | claimed |
| WO-2002050079-A1 | CYCLIN-DEPENDENT KINASE (CDK) AND GLYCOLENE SYNTHASE KINASE-3 (GSK-3) INHIBITORS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-06-27 | — | — | WO | claimed |
| EP-1438039-A2 | PRODUCT COMPRISING MIKANOLIDE, DIHYDROMIKANOLIDE OR AN ANALOGUE THEREOF COMBINED WITH ANOTHER ANTI-CANCER AGENT FOR THERAPEUTIC USE IN CANCER TREATMENT | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-07-21 | — | — | EP | disclosed |
| US-20040138245-A1 | Product comprising mikanolide, dihydromikanolide or an analogue thereof combine with another anti-cancer agent for therapeutic use in cancer treatment | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-07-15 | — | — | US | disclosed |
| US-20040048849-A1 | Cyclin-dependent kinase (cdk) and glycolene synthase kinase-3 (gsk-3) inhibitors | IPSEN PHARMA S.A.S. (FR) | 2004-03-11 | — | — | US | disclosed |
| EP-1345941-A1 | CYCLIN-DEPENDENT KINASE (CDK) AND GLYCOLENE SYNTHASE KINASE-3 (GSK-3) INHIBITORS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002096348-A2 | PRODUCT COMPRISING MIKANOLIDE, DIHYDROMIKANOLIDE OR AN ANALOGUE THEREOF COMBINED WITH ANOTHER ANTI-CANCER AGENT FOR THERAPEUTIC USE IN CANCER TREATMENT | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-12-05 | — | — | WO | disclosed |
| WO-2002050079-A1 | CYCLIN-DEPENDENT KINASE (CDK) AND GLYCOLENE SYNTHASE KINASE-3 (GSK-3) INHIBITORS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048849-A1 | Cyclin-dependent kinase (cdk) and glycolene synthase kinase-3 (gsk-3) inhibitors | CDK1, CDK3, CDKL3 | KDM4E 2007/4885MAPT 3427/4885ALDH1A1 1268/4885 |
| US-20040138245-A1 | Product comprising mikanolide, dihydromikanolide or an analogue thereof combine with another anti-cancer agent for therapeutic use in cancer treatment | DTYMK, DGKG, DGKZ | KDM4E 1290/4885MAPT 4856/4885ALDH1A1 2034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.